Cognition Therapeutics, Inc. Increase (Decrease) in Accrued Liabilities
Cognition Therapeutics, Inc. (CGTX) reported Increase (Decrease) in Accrued Liabilities of $343.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-23.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2023-03-23
- Cognition Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2022-12-31 was -$220.00K, a 121.76% decline year-over-year.
- Cognition Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2022-09-30 was $647.00K.
- Cognition Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2022-06-30 was $284.00K, a 72.77% decline year-over-year.
- Cognition Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2022-03-31 was -$368.00K, a 232.85% decline year-over-year.
- Cognition Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2022 was $343.00K, a 72.97% decline from fiscal 2021.
- Cognition Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2021 was $1.27M, a 113.28% increase from fiscal 2020.
- Cognition Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2020 was $595.00K.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2022-12-31 | -$220.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $427.00K derived: sum of 2 quarters · filed 2023-03-23 | $711.00K derived: sum of 3 quarters · filed 2023-03-23 | $343.00K 10-K · filed 2023-03-23 |
| 2022-09-30 | $647.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $931.00K derived: sum of 2 quarters · filed 2022-11-14 | $563.00K 10-Q · filed 2022-11-14 | $1.57M derived: sum of 4 quarters · filed 2023-03-23 |
| 2022-06-30 | $284.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$84.00K 10-Q · filed 2022-08-09 | $927.00K derived: sum of 3 quarters · filed 2023-03-23 | -$135.00K derived: sum of 4 quarters · filed 2023-03-23 |
| 2022-03-31 | -$368.00K 10-Q · filed 2022-05-11 | $643.00K derived: sum of 2 quarters · filed 2023-03-23 | -$419.00K derived: sum of 3 quarters · filed 2023-03-23 | $624.00K derived: sum of 4 quarters · filed 2023-03-23 |
| 2021-12-31 | $1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$51.00K derived: sum of 2 quarters · filed 2023-03-23 | $992.00K derived: sum of 3 quarters · filed 2023-03-23 | $1.27M 10-K · filed 2023-03-23 |
| 2021-09-30 | -$1.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$19.00K derived: sum of 2 quarters · filed 2022-11-14 | $258.00K 10-Q · filed 2022-11-14 | $578.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $1.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $1.32M 10-Q · filed 2022-08-09 | $1.64M derived: sum of 3 quarters · filed 2022-08-09 | |
| 2021-03-31 | $277.00K 10-Q · filed 2022-05-11 | $597.00K derived: sum of 2 quarters · filed 2022-05-11 | ||
| 2020-12-31 | $320.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $595.00K 10-K · filed 2022-03-30 | ||
| 2020-09-30 | $275.00K 10-Q · filed 2021-11-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |